Inventiva S.A. American Depository Shares (IVA) Stock Price
IVAStock
$2.94−12.76%52W
Market Cap$694.49M
P/E—
PEG Ratio—
Div yield—
Beta-0.45
IVA Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-53.16%
Price vs S&P 500 (4W)-11.57%
VGM Score30.25
IVA Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.44
4.44
4.41
4.41
Industry Peers — Pharmaceuticals(574)
| Symbol | Value Score | Growth Score | Momentum Score | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|---|---|---|
IVAInventiva S.A. American Depository Shares | F | D | C | 150.5x | -51.3% | — | — | $2.94 |
| LLYEli Lilly & Co. | D | B | A | 14.9x | 49.6% | 83.4% | 27.6% | $1257.03 |
| JNJJohnson & Johnson | D | C | B | 6.2x | 7.8% | 67.7% | 14.9% | $255.56 |
| ABBVABBVIE INC. | D | C | A | 7.8x | 10.4% | 72.8% | -2.9% | $285.42 |
| MRKMerck & Co., Inc. | D | C | A | 5.4x | 4.6% | 77.3% | 21.2% | $145.95 |
| NVSNovartis AG | C | C | B | 4.9x | 3.3% | 75.0% | 15.3% | $150.62 |
| AZNAstraZeneca PLC | C | B | B | 4.3x | 8.6% | 81.3% | 21.9% | $165.41 |
| ABTAbbott Laboratories | C | C | B | 3.9x | 8.1% | 56.8% | 8.2% | $104.89 |
| NVONovo-Nordisk A/S | B | C | C | 3.5x | 5.6% | 80.7% | 20.7% | $38.83 |
| PFEPfizer Inc. | C | D | A | 2.6x | -0.2% | 74.7% | -3.5% | $29.58 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | 10.1x | 10.2% | 86.0% | 8.3% | $499.74 |
About Inventiva S.A. American Depository Shares
Inventiva SA is a French biopharmaceutical company developing drug candidates targeting nuclear receptors and epigenetic pathways. Its lead program, lanifibranor, is being advanced for non-alcoholic steatohepatitis (NASH), a disease with no currently approved treatments, representing a significant commercial opportunity. The company maintains a pre-clinical pipeline in oncology, fibrosis, and rare diseases, and generates revenue through research partnerships with major pharmaceutical partners including AbbVie and BI.